News / Taiwan / economic_daily
TWSE Clarifies Market Impact Data for Pei-E Biomedical Following Stock Split
Health Technology · Biotechnology · economic_daily · 2026-08-26
2330, 2454, 6949
The Taiwan Stock Exchange has corrected viral reports claiming Pei-E Biomedical contributed nearly 60 points to the index, citing a calculation error by third-party platforms during its 1-for-20 stock split.
What Happened
Data Discrepancy Clarification: The Taiwan Stock Exchange (TWSE) has officially corrected viral reports claiming that Pei-E Biomedical contributed 59.4 points to the benchmark index in a single day. Officials clarified that the actual contribution was approximately 2.71 points, noting that the company's impact on the index is significantly lower than suggested by erroneous third-party data.
Impact of Stock Split: Pei-E Biomedical recently executed a 1-for-20 stock split to lower entry barriers and enhance liquidity on the Innovation Board. The confusion stemmed from automated systems on various financial websites failing to synchronize the adjusted share count and weighting factors during the transition period.
Fundamental Performance: Despite an 87% surge in share price during August, the company remains unprofitable, reporting losses for the first half of the year and declining revenue for July. As a biotech firm focused on CAR-T cell therapy, the company is still in the clinical trial and drug approval phase, highlighting a disconnect between its market valuation and financial results.
Market Outlook: With the final trading day before the split concluded, new shares are scheduled to resume trading on September 7. Market participants are now closely monitoring whether the split will successfully improve liquidity and how the stock will perform once trading resumes under the new structure.